Adenocarcinomas nasosinusales tipo intestinal. Perfil inmunohistoquímico de 66 casos

Allende, Blanca Vivanco; Pérez-Escuredo, Jhudit; Martínez, Nelson Fuentes; Forcelledo, Manuel F. Fresno; Llorente, José Luís; Hermsen, Mario

doi:10.1016/j.otorri.2012.09.002

Cited by 12 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The absence of squamous differentiation distinguishes ITAC from mucoepidermoid carcinoma and adenosquamous carcinoma [49,50,53,54]. Molecular alterations observed in ITACs are mainly mutations in the TP53 genes (60%) [54] and overexpression of EGFR or HER2 (30%) [55][56][57][58]. The rate of TP53 mutations in ITACs is about 60% and, interestingly, it is related to the duration, average and cumulative level of exposure to wood dust [53][54][55].…”

Section: Intestinal Adenocarcinomamentioning

confidence: 99%

Malignant Sinonasal Tumors: Update on Histological and Clinical Management

et al. 2021

View full text Add to dashboard Cite

Tumors of nasal cavity and paranasal sinuses (TuNSs) are rare and heterogeneous malignancies, presenting different histological features and clinical behavior. We reviewed the literature about etiology, biology, and clinical features of TuNSs to define pathologic features and possible treatment strategies. From a diagnostic point of view, it is mandatory to have high expertise and perform an immunohistochemical assessment to distinguish between different histotypes. Due to the extreme rarity of these neoplasms, there are no standard and evidence-based therapeutic strategies, lacking prospective and large clinical trials. In fact, most studies are retrospective analyses. Surgery represents the mainstay of treatment of TuNSs for small and localized tumors allowing complete tumor removal. Locally advanced lesions require more demolitive surgery that should be always followed by adjuvant radio- or chemo-radiotherapy. Recurrent/metastatic disease requires palliative chemo- and/or radiotherapy. Many studies emphasize the role of specific genes mutations in the development of TuNSs like mutations in the exons 4–9 of the TP53 gene, in the exon 9 of the PIK3CA gene and in the promoter of the TERT gene. In the near future, this genetic assessment will have new therapeutic implications. Future improvements in the understanding of the etiology, biology, and clinical features of TuNSs are warranted to improve their management.

show abstract